Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease

Human Molecular Genetics

Volumn 19, Issue 17, 2010, Pages 3354-3371

  Perry, Giselle M ^a   Tallaksen Greene, Sara ^d,e   Kumar, Ashish ^a   Heng, Mary Y ^d,e   Kneynsberg, Andrew ^a   van Groen, Thomas ^b   Detloff, Peter J ^c   Albin, Roger L ^d,e   Lesort, Mathieu ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d VAAAHS   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CYCLOPHILIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR; BRAIN MITOCHONDRION; CAG REPEAT; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; FEMALE; GENE DELETION; GENE EXPRESSION; GRIP STRENGTH; HUNTINGTON CHOREA; KNOCKOUT MOUSE; LIFESPAN; LOCOMOTION; MALE; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NONHUMAN; PATHOGENESIS; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; ROTAROD TEST; SURVIVAL; TRANSGENIC MOUSE; WEIGHT CHANGE;

ANIMALS; BIOLOGICAL TRANSPORT; CALCIUM; CYCLOPHILINS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MITOCHONDRIA; NEURONS;

MUS; MUS MUSCULUS;

EID: 77955383022     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq247     Document Type: Article

References (70)

1. Folstein, S.E. (1989) Huntington's Disease: a Disorder of Families. Johns Hopkins University Press, Baltimore.
2. Hunter, J.M., Crouse, A.B., Lesort, M., Johnson, G.V. and Detloff, P.J. (2005) Verification of somatic CAG repeat expansion by pre-PCR fractionation. J. Neurosci. Methods, 144, 11-17.
3. Trottier, Y., Biancalana, V. and Mandel, J.L. (1994) Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. J. Med. Genet., 31, 377-382.
4. Telenius, H., Kremer, B., Goldberg, Y.P., Theilmann, J., Andrew, S.E., Zeisler, J., Adam, S., Greenberg, C., Ives, E.J., Clarke, L.A. et al. (1994) Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. Nat. Genet., 6, 409-414.
5. Kennedy, L., Evans, E., Chen, C.M., Craven, L., Detloff, P.J., Ennis, M. and Shelbourne, P.F. (2003) Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum. Mol. Genet., 12, 3359-3367.
6. Kennedy, L. and Shelbourne, P.F. (2000) Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease? Hum. Mol. Genet., 9, 2539-2544.
7. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
8. Myers, R.H. (2004) Huntington's disease genetics. NeuroRx, 1, 255-262.
9. McNeil, S.M., Novelletto, A., Srinidhi, J., Barnes, G., Kornbluth, I., Altherr, M.R., Wasmuth, J.J., Gusella, J.F., MacDonald, M.E. and Myers, R.H. (1997) Reduced penetrance of the Huntington's disease mutation. Hum. Mol. Genet., 6, 775-779.
10. Gusella, J.F. and MacDonald, M.E. (1996) Trinucleotide instability: a repeating theme in human inherited disorders. Annu. Rev. Med., 47, 201-209.
11. Vonsattel, J.P. and DiFiglia, M. (1998) Huntington disease. J. Neuropathol. Exp. Neurol., 57, 369-384.
12. Rosas, H.D., Koroshetz, W.J., Chen, Y.I., Skeuse, C., Vangel, M., Cudkowicz, M.E., Caplan, K., Marek, K., Seidman, L.J., Makris, N. et al. (2003) Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology, 60, 1615-1620.
13. Rosas, H.D., Liu, A.K., Hersch, S., Glessner, M., Ferrante, R.J., Salat, D.H., van der Kouwe, A., Jenkins, B.G., Dale, A.M. and Fischl, B. (2002) Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology, 58, 695-701.
14. Rosas, H.D., Goodman, J., Chen, Y.I., Jenkins, B.G., Kennedy, D.N., Makris, N., Patti, M., Seidman, L.J., Beal, M.F. and Koroshetz, W.J. (2001) Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology, 57, 1025-1028.
15. Trushina, E., Dyer, R.B., Badger, J.D. II, Ure, D., Eide, L., Tran, D.D., Vrieze, B.T., Legendre-Guillemin, V., McPherson, P.S., Mandavilli, B.S. et al. (2004) Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell Biol., 24, 8195-8209.
16. DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.P., Carraway, R., Reeves, S.A. et al. (1995) Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron, 14, 1075-1081.
17. Kegel, K.B., Kim, M., Sapp, E., McIntyre, C., Castano, J.G., Aronin, N. and DiFiglia, M. (2000) Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J. Neurosci., 20, 7268-7278.
18. Wheeler, V.C., White, J.K., Gutekunst, C.A., Vrbanac, V., Weaver, M., Li, X.J., Li, S.H., Yi, H., Vonsattel, J.P., Gusella, J.F. et al. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet., 9, 503-513.
19. Kegel, K.B., Meloni, A.R., Yi, Y., Kim, Y.J., Doyle, E., Cuiffo, B.G., Sapp, E., Wang, Y., Qin, Z.H., Chen, J.D. et al. (2002) Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem., 277, 7466-7476.
20. Choo, Y.S., Johnson, G.V., MacDonald, M., Detloff, P.J. and Lesort, M. (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet., 13, 1407-1420.
21. Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.W., Saiki, S., Rose, C., Krishna, G., Davies, J.E., Ttofi, E., Underwood, B.R. et al. (2008) Huntington's disease: from pathology and genetics to potential therapies. Biochem. J., 412, 191-209.
22. Nucifora, F.C. Jr, Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L. et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science, 291, 2423-2428.
23. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E. and Thompson, L.M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 97, 6763-6768.
24. Li, H., Li, S.H., Yu, Z.X., Shelbourne, P. and Li, X.J. (2001) Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci., 21, 8473-8481.
25. Gunawardena, S., Her, L.S., Brusch, R.G., Laymon, R.A., Niesman, I.R., Gordesky-Gold, B., Sintasath, L., Bonini, N.M. and Goldstein, L.S. (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron, 40, 25-40.
26. Beal, M.F. (1994) Huntington's disease, energy, and excitotoxicity. Neurobiol. Aging, 15, 275-286.
27. Bossy-Wetzel, E., Petrilli, A. and Knott, A.B. (2008) Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci., 31, 609-616.
28. Browne, S.E. (2008) Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann. N. Y. Acad. Sci., 1147, 358-382.
29. 2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl Acad. Sci. USA, 102, 2602-2607.
30. Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J. and Greenamyre, J.T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 5, 731-736.
31. Oliveira, J.M., Jekabsons, M.B., Chen, S., Lin, A., Rego, A.C., Goncalves, J., Ellerby, L.M. and Nicholls, D.G. (2007) Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J. Neurochem., 101, 241-249.
32. Milakovic, T., Quintanilla, R.A. and Johnson, G.V. (2006) Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J. Biol. Chem., 281, 34785-34795.
33. 2+ in R6/2 mice. Ann. Neurol., 59, 407-411.
34. 2+ in transgenic Huntington disease rats. J. Biol. Chem., 283, 30715-30724.
35. Brustovetsky, N., LaFrance, R., Purl, K.J., Brustovetsky, T., Keene, C.D., Low, W.C. and Dubinsky, J.M. (2005) Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's disease. J. Neurochem., 93, 1361-1370.
36. Schinzel, A.C., Takeuchi, O., Huang, Z., Fisher, J.K., Zhou, Z., Rubens, J., Hetz, C., Danial, N.N., Moskowitz, M.A. and Korsmeyer, S.J. (2005) Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc. Natl Acad. Sci. USA, 102, 12005-12010.
37. Nakagawa, T., Shimizu, S., Watanabe, T., Yamaguchi, O., Otsu, K., Yamagata, H., Inohara, H., Kubo, T. and Tsujimoto, Y. (2005) Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature, 434, 652-658.
38. Baines, C.P., Kaiser, R.A., Purcell, N.H., Blair, N.S., Osinska, H., Hambleton, M.A., Brunskill, E.W., Sayen, M.R., Gottlieb, R.A., Dorn, G.W. et al. (2005) Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature, 434, 658-662.
39. Basso, E., Fante, L., Fowlkes, J., Petronilli, V., Forte, M.A. and Bernardi, P. (2005) Properties of the permeability transition pore in mitochondria devoid of cyclophilin D. J. Biol. Chem., 280, 18558-18561.
40. Forte, M., Gold, B.G., Marracci, G., Chaudhary, P., Basso, E., Johnsen, D., Yu, X., Fowlkes, J., Rahder, M., Stem, K. et al. (2007) Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc. Natl Acad. Sci. USA, 104, 7558-7563.
41. Du, H., Guo, L., Fang, F., Chen, D., Sosunov, A.A., McKhann, G.M., Yan, Y., Wang, C., Zhang, H., Molkentin, J.D. et al. (2008) Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med., 14, 1097-1105.
42. Vonsattel, J.P. (2008) Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol., 115, 55-69.
43. Stack, E.C., Kubilus, J.K., Smith, K., Cormier, K., Del Signore, S.J., Guelin, E., Ryu, H., Hersch, S.M. and Ferrante, R.J. (2005) Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol., 490, 354-370.
44. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
45. Hockly, E., Woodman, B., Mahal, A., Lewis, C.M. and Bates, G. (2003) Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res. Bull., 61, 469-479.
46. Baines, C.P., Kaiser, R.A., Sheiko, T., Craigen, W.J. and Molkentin, J.D. (2007) Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat. Cell Biol., 9, 550-555.
47. Browne, S.E., Bowling, A.C., MacGarvey, U., Baik, M.J., Berger, S.C., Muqit, M.M., Bird, E.D. and Beal, M.F. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol., 41, 646-653.
48. Goebel, H.H., Heipertz, R., Scholz, W., Iqbal, K. and Tellez-Nagel, I. (1978) Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology, 28, 23-31.
49. Tabrizi, S.J., Cleeter, M.W., Xuereb, J., Taanman, J.W., Cooper, J.M. and Schapira, A.H. (1999) Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol., 45, 25-32.
50. Taylor-Robinson, S.D., Weeks, R.A., Bryant, D.J., Sargentoni, J., Marcus, C.D., Harding, A.E. and Brooks, D.J. (1996) Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov. Disord., 11, 167-173.
51. Seong, I.S., Ivanova, E., Lee, J.M., Choo, Y.S., Fossale, E., Anderson, M., Gusella, J.F., Laramie, J.M., Myers, R.H., Lesort, M. et al. (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet., 14, 2871-2880.
52. Guidetti, P., Charles, V., Chen, E.Y., Reddy, P.H., Kordower, J.H., Whetsell, W.O. Jr, Schwarcz, R. and Tagle, D.A. (2001) Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp. Neurol., 169, 340-350.
53. Powers, W.J., Videen, T.O., Markham, J., McGee-Minnich, L., Antenor-Dorsey, J.V., Hershey, T. and Perlmutter, J.S. (2007) Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc. Natl Acad. Sci. USA, 104, 2945-2949.
54. Fernandes, H.B., Baimbridge, K.G., Church, J., Hayden, M.R. and Raymond, L.A. (2007) Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J. Neurosci., 27, 13614-13623.
55. Orr, A.L., Li, S., Wang, C.E., Li, H., Wang, J., Rong, J., Xu, X., Mastroberardino, P.G., Greenamyre, J.T. and Li, X.J. (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci., 28, 2783-2792.
56. Crompton, M., Virji, S., Doyle, V., Johnson, N. and Ward, J.M. (1999) The mitochondrial permeability transition pore. Biochem. Soc. Symp., 66, 167-179.
57. Ferrante, R.J., Kowall, N.W., Cipolloni, P.B., Storey, E. and Beal, M.F. (1993) Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp. Neurol., 119, 46-71.
58. Young, A.B., Greenamyre, J.T., Hollingsworth, Z., Albin, R., D'Amato, C., Shoulson, I. and Penney, J.B. (1988) NMDA receptor losses in putamen from patients with Huntington's disease. Science, 241, 981-983.
59. Albin, R.L. and Greenamyre, J.T. (1992) Alternative excitotoxic hypotheses. Neurology, 42, 733-738.
60. Heng, M.Y., Detloff, P.J., Wang, P.L., Tsien, J.Z. and Albin, R.L. (2009) In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J. Neurosci., 29, 3200-3205.
61. Kushnareva, Y.E., Wiley, S.E., Ward, M.W., Andreye, A.Y. and Murphy, A.N. (2006) Excitotoxic injury to mitochondria isolated from cultured neurons. J. Biol. Chem., 280, 28894-28902.
62. 2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J. Neurosci., 26, 11174-11186.
63. 2+ rise upon hypoxia/reoxygenation for functional breakdown and morphological disintegration. J. Biol. Chem., 278, 25454-25460.
64. Reynolds, I.J. and Hastings, T.G. (1995) Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J. Neurosci., 15, 3318-3327.
65. Lin, D.T. and Lechleiter, J.D. (2002) Mitochondrial targeted cyclophilin D protects cells from cell death by peptidyl prolyl isomerization. J. Biol. Chem., 277, 31134-31141.
66. Heng, M.Y., Detloff, P.J. and Albin, R.L. (2008) Rodent genetic models of Huntington disease. Neurobiol. Dis., 32,1-9.
67. Menalled, L., El-Khodor, B.F., Patry, M., Suárez-Fariñas, M., Orenstein, S.J., Zahasky, B., Leahy, C., Wheeler, V., Yang, X.W., MacDonald, M. et al. (2009) Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis., 35, 319-336.
68. Morton, A.J., Glynn, D., Leavens, W., Zheng, Z., Faull, R.L.M., Skepper, J.N. and Wight, J.M. (2009) Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol. Dis., 33, 331-341.
69. Choo, Y.S., Mao, Z., Johnson, G.V. and Lesort, M. (2005) Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model. Neurosci. Lett., 386, 63-68.
70. Paxinos, G. and Franklin, K. (ed.) (2001) The Mouse Brain in Stereotaxic Coordinates, 2nd edn. Academic, San Diego.